May 30, 2019
Teijin Pharma rolled out Japan’s first adenosine deaminase (ADA) deficiency treatment Revcovi 2.4 mg for intramuscular injection (elapegademase) on May 29 . ADA deficiency is an ultra-rare immune deficiency condition caused by a lack of ADA activity due to gene...read more